Dr Reddy’s must warn Celgene of plans to sell generic blockbuster cancer drug

Intellectual Property 2021-12-07 2:55 pm By Cindy Cameronne Sydney

Make us a preferred source Make us a preferred source on Google

Indian generics giant Dr Reddy’s Laboratories must give Bristol-Myers Squib unit Celgene Corporation three months’ notice before deciding to sell generic versions of blockbuster cancer drug Revlimid in Australia.